List of Excipients in API ENTRECTINIB
✉ Email this page to a colleague
Excipients in NDA-approved (novel) drugs containing ENTRECTINIB
| Company | Tradename | Ingredient | NDC | Excipient | Potential Generic Entry |
|---|---|---|---|---|---|
| Genentech Inc | ROZLYTREK | entrectinib | 50242-091 | ANHYDROUS LACTOSE | 2038-07-18 |
| Genentech Inc | ROZLYTREK | entrectinib | 50242-091 | CELLULOSE, MICROCRYSTALLINE | 2038-07-18 |
| Genentech Inc | ROZLYTREK | entrectinib | 50242-091 | CROSPOVIDONE | 2038-07-18 |
| Genentech Inc | ROZLYTREK | entrectinib | 50242-091 | FERRIC OXIDE YELLOW | 2038-07-18 |
| Genentech Inc | ROZLYTREK | entrectinib | 50242-091 | HYPROMELLOSE | 2038-07-18 |
| Genentech Inc | ROZLYTREK | entrectinib | 50242-091 | MAGNESIUM STEARATE | 2038-07-18 |
| >Company | >Tradename | >Ingredient | >NDC | >Excipient | >Potential Generic Entry |
Detailed excipient profiles for ENTRECTINIB
Excipient focus: ANHYDROUS LACTOSE
ENTRECTINIB drug variants containing ANHYDROUS LACTOSE
| Company | Ingredient | NDC |
|---|---|---|
| Genentech Inc | entrectinib | 50242-091 |
| >Company | >Ingredient | >NDC |
ENTRECTINIB drug variants not containing ANHYDROUS LACTOSE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: CELLULOSE, MICROCRYSTALLINE
ENTRECTINIB drug variants containing CELLULOSE, MICROCRYSTALLINE
| Company | Ingredient | NDC |
|---|---|---|
| Genentech Inc | entrectinib | 50242-091 |
| >Company | >Ingredient | >NDC |
ENTRECTINIB drug variants not containing CELLULOSE, MICROCRYSTALLINE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: CROSPOVIDONE
ENTRECTINIB drug variants containing CROSPOVIDONE
| Company | Ingredient | NDC |
|---|---|---|
| Genentech Inc | entrectinib | 50242-091 |
| >Company | >Ingredient | >NDC |
ENTRECTINIB drug variants not containing CROSPOVIDONE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: FERRIC OXIDE YELLOW
ENTRECTINIB drug variants containing FERRIC OXIDE YELLOW
| Company | Ingredient | NDC |
|---|---|---|
| Genentech Inc | entrectinib | 50242-091 |
| >Company | >Ingredient | >NDC |
ENTRECTINIB drug variants not containing FERRIC OXIDE YELLOW
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: HYPROMELLOSE
ENTRECTINIB drug variants containing HYPROMELLOSE
| Company | Ingredient | NDC |
|---|---|---|
| Genentech Inc | entrectinib | 50242-091 |
| >Company | >Ingredient | >NDC |
ENTRECTINIB drug variants not containing HYPROMELLOSE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: MAGNESIUM STEARATE
ENTRECTINIB drug variants containing MAGNESIUM STEARATE
| Company | Ingredient | NDC |
|---|---|---|
| Genentech Inc | entrectinib | 50242-091 |
| >Company | >Ingredient | >NDC |
ENTRECTINIB drug variants not containing MAGNESIUM STEARATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: PROPYLENE GLYCOL
ENTRECTINIB drug variants containing PROPYLENE GLYCOL
| Company | Ingredient | NDC |
|---|---|---|
| Genentech Inc | entrectinib | 50242-091 |
| >Company | >Ingredient | >NDC |
ENTRECTINIB drug variants not containing PROPYLENE GLYCOL
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: SHELLAC
ENTRECTINIB drug variants containing SHELLAC
| Company | Ingredient | NDC |
|---|---|---|
| Genentech Inc | entrectinib | 50242-091 |
| >Company | >Ingredient | >NDC |
ENTRECTINIB drug variants not containing SHELLAC
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: SILICON DIOXIDE
ENTRECTINIB drug variants containing SILICON DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| Genentech Inc | entrectinib | 50242-091 |
| >Company | >Ingredient | >NDC |
ENTRECTINIB drug variants not containing SILICON DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: TARTARIC ACID
ENTRECTINIB drug variants containing TARTARIC ACID
| Company | Ingredient | NDC |
|---|---|---|
| Genentech Inc | entrectinib | 50242-091 |
| >Company | >Ingredient | >NDC |
ENTRECTINIB drug variants not containing TARTARIC ACID
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: TITANIUM DIOXIDE
ENTRECTINIB drug variants containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| Genentech Inc | entrectinib | 50242-091 |
| >Company | >Ingredient | >NDC |
ENTRECTINIB drug variants not containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2025 - 2026
NCE-1 Patent Challenge Dates 2025 - 2026
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2025, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch